Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 24, 2020
Daily News
June 24, 2020
- 7 Authorized Generics in June Listing Target Combined 260 Billion Yen Market; Simultaneous Launches Catching On
June 24, 2020
- Rohto to Launch Stem Cell Clinical Trial for COVID-19 in August, Eyes Conditional OK
June 24, 2020
- AMED to Fund 29 New Research Projects to Develop COVID-19 Treatments, including 5 Company-Led Projects
June 24, 2020
- Pfizer Japan Draws Up Post-COVID-19 “New Normal Roadmap,” Easing Voluntary Restrictions in Phases
June 24, 2020
- US FDA Accepts Relugolix for Review in Advanced Prostate Cancer
June 24, 2020
- MHLW Grants Orphan Status to Venetoclax, 5 Other APIs
June 24, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…